Term ends Apr 20, 2031 · High confidence
20-year base term ends Dec 6, 2030
Held by Bioverativ Therapeutics Inc.
Filed Feb 7, 2019 as application 16/270,302 · Granted Mar 8, 2022
Base term plus 164 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
2010
2031
Clock starts
Dec 6, 2010
Dec 6, 2010
Term ends
Apr 20, 2031
Apr 20, 2031
Granted
Mar 8, 2022
Mar 8, 2022
base term
patent term adjustment
fee events
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
164
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 10,786,554, US 9,050,318.
1 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
6
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term runs 164 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 1 of 2 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 6, 2010, when application PCT/US2010/059136, the earliest non-provisional in its chain, was filed (this one was filed Feb 7, 2019) | Dec 6, 2030 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +164 days, USPTO patent term adjustment record | May 19, 2031 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,786,554, US 9,050,318) | capped to Apr 20, 2031 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Apr 20, 2031 | High confidence |
This family
| Application PCT/US2010/059136 | PCT application no patent term | no patent term |
| US 9,050,318 | In force Apr 2031 | Apr 2031 |
| US 9,241,978 | In force May 2031 | May 2031 |
| Application 14/964,289 | Abandoned not computed | not computed |
| US 11,266,720 | this patent Apr 2031 | Apr 2031 |
| Application 17/587,941 | Pending not computed | not computed |
Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jan 27, 2022 Reel 58886, frame 600 | Dumont, Jennifer A.; Low, Susan; Bitonti, Alan J.; Pierce, Glenn; Luk, Alvin; Jiang, Haiyan; McKinney, Byron; Ottmer, Matt; Sommer, Jurg; Nugent, Karen; Li, Lian; Peters, Robert | Biogen Idec Hemophilia Inc. | Assignment of Assignor's Interest |
| Jan 27, 2022 Reel 58886, frame 632 | Biogen Idec Hemophilia Inc. | Biogen Hemophilia Inc. | Change of Name |
| Jan 27, 2022 Reel 58886, frame 687 | Biogen Hemophilia Inc. | Bioverativ Therapeutics Inc. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Apr 2031
Term ends Apr 20, 2031. Maintenance fees still fall due before then
Note
The 164 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 10,786,554, US 9,050,318.
Citations
6
later US patents cite this one
That is top 25% of utility patents granted in 2022 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.